FACTSHEET | September 2026

Cantor Fitzgerald Green Effects Fund

Fund Objectives

The objective of the fund is to achieve long term capital growth through a basket of ethically screened stocks. The fund invests in a wide range of companies with a commitment to either supporting the environment or demonstrating a strong corporate responsibility ethos. Sectors such as wind energy, solar energy, electric vehicles, recycling, waste management, forestry and water-related businesses all feature prominently within the fund. The fund is actively managed and can only invest in the constituents of the Natural Stock Index (NAI) which was set up in 1994 and currently consists of 30 global equities.

Green Effects Fund NAV Since Inception



Source: Cantor Fitzgerald Ireland Ltd Research

Performance data quoted represents past performance. Past performance does not guarantee future returns.

Largest Thematic Exposure %



Geographic Exposure %



Key Information

Morningstar Rating:
★★★★

Morningstar Analyst Rating:
Bronze

SFDR Designation:
Article 9

Fund Inception:
Oct 2000

NAV:
€479.03

NAV Date:
31/08/26

Dealing Frequency:
Daily

Investment Manager:
Cantor Fitzgerald Ireland Ltd

Manager:
Fundrock Management Company

Custodian & Administrator:
Northern Trust

Lead Fund Manager:
Richard Power

Co Managers:
Aidan Graver
Graham O'Brien

Investment Mgt Fee:
0.75%

Source: Bloomberg & Cantor Fitzgerald Ireland Ltd Research

Fund & Share Class Information

Fund Size	€198.59m
Fund ISIN	IE0005895655
Fund Sedol	0589565
Domicile	Ireland
Structure	UCITS Fund

email: **greeneffects@cantor.com**

Performance

	1 Month	YTD	1 Year	3 Year*	5 Year*	10 Year*	Inception*
Green Effects	1.81%	11.71%	23.66%	10.76%	3.38%	9.84%	6.08%
MSCI World €	1.72%	14.67%	21.75%	17.88%	12.11%	13.15%	6.75%
S&P 500 €	1.84%	14.28%	21.23%	18.24%	13.13%	14.88%	7.61%

*As of 31/08/2026. Source: Cantor Fitzgerald Ireland Ltd Research, Bloomberg and Northern Trust. *Annualised Return.*

Performance data quoted represents past performance. Past performance does not guarantee future returns.
Green Effects reference index is the NAI Index, Equity indices above for illustrative purposes only.

Fund Sector Exposure vs MSCI World

Sectors	Green Effects	MSCI World
Information Technology	12.1%	29.81%
Financials	4.6%	16.58%
Health Care	14.2%	9.27%
Consumer Discretionary	10.1%	8.82%
Industrials	27.5%	11.13%
Communication Services	0.0%	7.90%
Consumer Staples	5.4%	4.91%
Materials	8.4%	3.47%
Energy	0.0%	4.09%
Utilities	6.8%	2.39%
Real Estate	7.6%	1.59%
Cash	3.2%	0

Source: Cantor Fitzgerald Ireland Ltd Research

ESG Rating

	Fund	MSCI World
MSCI ESG Rating	AA	A
MSCI Avg ESG Score	7.9	6.8
MSCI Quality	7.91	6.75
MSCI Carbon Intensity	52	140

Total number of holdings

Number of holdings	30

Market Capitalisation Exposure

Greater than 3bn	73.3%
Medium 500m - 3bn	23.3%
Small Less than 500m	3.3%

Annual Returns

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
23.95%	22.52%	6.42%	-38.47%	31.28%	13.47%	-19.61%	16.02%	19.87%	18.42%	15.72%
2016	**2017**	**2018**	**2019**	**2020**	**2021**	**2022**	**2023**	**2024**	**2025**	**2026**
6.62%	6.8%	-5.91%	23.34%	42.70%	19.78%	-19.70%	13.94%	5.79%	8.86%	11.17%

Source: Cantor Fitzgerald Ltd Research, Bloomberg and Northern Trust.
Performance data quoted represents past performance. Past performance does not guarantee future returns.

ESMA Risk Rating

LOWER RISK HIGHER RISK

1 2 3 4 5 **6** 7

email: **greeneffects@cantor.com**

Top 20 Positions

VESTAS	6.38%
FIRST SOLAR	5.39%
KINGFISHER	4.90%
HANNON ARMSTRONG	4.65%
SMITH & NEPHEW	4.60%
WELLTOWER	4.05%
TESLA INC	3.99%
TOMRA SYSTEMS	3.92%
GEBERIT	3.84%
SIMS METAL	3.81%
UNITED NAT FOODS	3.76%
MOLINA	3.74%
SCATEC ASA	3.62%
RAYONIER	3.58%
INTERFACE	3.42%
NVIDIA	3.22%
ORMAT	3.16%
KURITA	3.12%
ASPEN PHARMACARE	3.04%
BIONTECH SE	2.83%

Source: Cantor Fitzgerald Ireland Ltd

Fund Manager Comment

The Green Effects Fund nav ended August at **€479.03** which was a return for the month of **+1.81%**. The largest positive contributors to the Fund move on the month were Vestas, Tesla, Interface, BioNTech and Geberit. Holdings that underperformed on the month included United Natural Foods, Smith & Nephew, First Solar and Raynonier.

The dominant market theme during August 2026 was not corporate earnings, geopolitics or AI enthusiasm, but rather the sharp rise in long-dated government bond yields. Equity markets spent much of the month attempting to digest a higher-for-longer interest rate environment, culminating in an unusually hawkish tone from the annual Jackson Hole meeting of Central Bankers. The Jackson Hole symposium held between 27-29 August 2026 was the first appearance by new Federal Reserve Chair Kevin Warsh. The key focus from commentary around that meeting centred on Inflation remaining above the Federal Reserve's 2% target and the fact that policymakers were unwilling to signal imminent rate cuts.

For context the 10yr US Govt Bond yield ended the month at 4.75%, its highest level since January 2025. Odds of rate hikes in Europe, the US and UK all edged higher during the month as Brent Oil closed just over $90 a barrel which was up 15% on the month on renewed US/Iranian military action. While the energy transition sector has historically struggled during any period of higher rates we view the current industry leaders (Vestas, First Solar etc) as being well placed to weather any immediate change in interest rates with stronger balance sheets, more prudent management of rate risks and more diversified global business models.

Key earnings and news call outs on the month included:

Tesla rose in the later part of the month ahead of its Cybercab event. The market will be looking for updates on self-driving robotaxis, which could help cut transport emissions and create a new long-term growth opportunity if Tesla can successfully launch and scale the service.

Nvidia reported very strong results as demand for AI computing remains extremely high. FY27 revenue guidance indicated at least ~70% growth year on year, driven by sustained demand from its largest customers and sold-out compute capacity.

Scatec reported earnings inline with expectations and showed production up 21%. The company continues to grow its solar and clean energy projects, increasing renewable electricity production despite some short-term operational challenges.

Geberit expects stronger sales growth than the market anticipated. The company benefits from energy-efficient building trends and has a strong track record of profitability, cash generation and market leadership in sustainable building products.

Vestas Wind Systems delivered much stronger profits than expected and increased its outlook for the year. As one of the world's largest wind turbine manufacturers, the company is benefiting from growing demand for renewable energy and improved profitability across its projects. Vestas remains the largest holding in the Fund.

Smith & Nephew cut its growth forecast after weaker sales in several healthcare divisions. While its products help improve patient health outcomes, the results suggest the company is still struggling to consistently deliver operational improvements.

First Solar gained strongly after positive earnings and supportive US policy developments. The company could benefit from greater protection for US-made solar panels, helping strengthen domestic renewable energy supply chains and supporting future growth.

Company Watch – BioNTech SE

BioNTech SE is a global next-generation biotechnology pioneer that harnesses the human immune system to treat cancer and infectious diseases. While most investors may know the company solely for developing the world's first widely approved mRNA COVID-19 vaccine (Comirnaty) alongside Pfizer, BioNTech's foundational mission has always been oncology (Cancer treatments). BioNTech was founded in Mainz, Germany, in 2008 by the husband-and-wife scientist team Dr. Ugur Sahin and Dr. Özlem Türeci. Their guiding philosophy was to create highly individualized cancer treatments tailored to a patient's specific genetic tumor profile.

When COVID-19 struck, BioNTech initiated "Project Lightspeed," successfully weaponizing their existing mRNA technology to bring a vaccine to market in record time. This generated tens of billions in revenue, equipping the company with a strong balance sheet to fully fund its pipeline without needing constant debt or dilutive share issuances.

BioNTech aligns directly with UN Sustainable Development Goal 3 (Good Health and Well-being). By developing therapies for high-recurrence, metastatic, and rare cancers, the company targets massive global healthcare gaps. BioNTech continues to re-invest its resources into clinical trials for neglected global killers, actively developing next-generation mRNA vaccines for tuberculosis, malaria, and influenza. The company boasts an immense clinical footprint, with over 25 Phase 2 and Phase 3 clinical trials ongoing. Rather than relying on a single "blockbuster" drug, they are building a synergistic matrix of treatments. Its most significant potential drug within its pipeline (Pumitamig) is specifically targeting Non-Small Cell Lung Cancer (NSCLC), Breast, and Ovarian Cancers. This particular drug is undergoing multiple Phase 3 pivotal trials and is backed by an $11B partnership deal with Bristol Myers Squibb.